IMMUNODIAGNOSTICS  |  IMMUNOMONITORINGImmuQuad Biotech   ·   Contact@ImmuQuad.com

What is measurable residual disease?

MRD refers to the small number of malignant cells that may remain after treatment even when routine clinical assessments indicate remission.

Conceptual illustration of detecting a rare disease-associated sequence
Beyond morphology

A deeper view of treatment response

Conventional morphology can confirm that the visible burden of disease has fallen substantially, but it may not reveal very low levels of residual malignant cells. Molecular and cellular MRD methods are used to evaluate disease at greater depth.

MRD should be interpreted as part of the complete clinical picture—not as a stand-alone treatment decision.Professional-use principle

At diagnosis or relapse

Obtain a high-disease-burden specimen and identify disease-associated molecular markers.

During treatment

Quantify marker levels to evaluate the depth and kinetics of response.

At key milestones

Assess MRD at protocol-defined time points, such as end of induction, end of consolidation or around transplantation.

During follow-up

Track molecular changes over time and evaluate unexpected or emerging clonal signals.

Clinical value

What MRD monitoring can contribute

✓

Response assessment

Provide a sensitive measure of how strongly disease-associated markers respond to therapy.

⚑

Risk information

MRD status and kinetics can add prognostic information in specific diseases and treatment settings.

↻

Longitudinal surveillance

Maintain a molecular record of known markers and identify changes that merit clinical review.

Method landscape

MRD methods answer related—but not identical—questions

Method selection depends on disease biology, available markers, sample type, protocol requirements, sensitivity goals and local validation.

MethodPrimary signalCommon strengthsConsiderations
Multiparameter flow cytometryAbnormal cellular immunophenotypeRapid, broad clinical experience, cell-level characterizationRequires viable, representative specimens and expert interpretation
Quantitative PCRDefined molecular targetHigh specificity and established standardization for selected markersRequires a suitable target and assay-specific calibration
Ig/TCR NGSPatient-specific immune receptor rearrangementHigh analytical depth, multiple-clone tracking, digital sequence recordRequires baseline marker identification and sufficient high-quality input

Discuss a Seq-MRD project with ImmuQuad

Clinical testing, translational research, clinical trials and biopharma collaborations.

Contact our team